Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing medicines in the field of cellular metabolism. Its lead product is PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK) enzymes, used to treat hemolytic anemias in adults with PK deficiency. PYRUKYND is also being studied in a phase 3 clinical trial for sickle cell disease. The company's portfolio includes AQVESME for adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. Additionally, Agios is developing tebapivat, a PK activator for lower-risk myelodysplastic syndrome and sickle cell disease, as well as AG-181 for phenylketonuria (PKU) and AG-236, an siRNA targeting TMPRSS6 for polycythemia vera.

Agios Pharmaceuticals is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol AGIO. The company's stock is traded in US Dollars (USD), as it is headquartered in the United States. Being listed on a major US exchange provides liquidity and visibility to investors worldwide.

Agios Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biopharmaceutical company, it focuses on researching and developing innovative therapies that target cellular metabolism to treat various diseases, including rare genetic disorders and blood conditions.

Agios Pharmaceuticals is headquartered in Cambridge, Massachusetts, United States. The company primarily serves the US market, as its products and clinical trials are focused on treatments approved or under investigation in the United States. Its lead product PYRUKYND is approved for adults with PK deficiency in the US, and its pipeline targets conditions like sickle cell disease and thalassemia, which affect patients globally but are initially addressed in the US.

Agios Pharmaceuticals has a robust pipeline centered on cellular metabolism. Its key approved product is PYRUKYND (mitapivat) for adults with PK deficiency, and it is also in phase 3 trials for sickle cell disease. AQVESME is approved for adult patients with alpha- or beta-thalassemia. In earlier stages, tebapivat is being developed for lower-risk myelodysplastic syndrome and sickle cell disease. Additionally, AG-181 targets phenylketonuria (PKU), and AG-236, an siRNA in-licensed from Alnylam, targets the TMPRSS6 gene for polycythemia vera. These products address significant unmet medical needs in rare blood disorders and metabolic diseases.